EcoDrugPlus

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSGACG00000000906
Gene Symbol: PARP3
1 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSGACG00000012184
Gene Symbol: PORCN
1 Cross references
195 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSGACG00000012800
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSGACG00000002248
Gene Symbol: KCNMA1
1 Cross references
244 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSGACG00000008829
Gene Symbol: KCNMA1
1 Cross references
227 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSGACG00000010191
Gene Symbol: KCNK2B
1 Cross references
214 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSGACG00000010038
Gene Symbol: KCNK3A
1 Cross references
203 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSGACG00000008919
Gene Symbol: KCNK9
1 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSGACG00000011042
Gene Symbol: KCNJ11
1 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSGACG00000010946
Gene Symbol: KCNJ2
1 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSGACG00000014451
Gene Symbol: KCNJ2A
1 Cross references
201 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSGACG00000005851
Gene Symbol: KCNJ3
1 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).